Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company focused on rare disease treatments, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss the results. The company will take live questions during the call and answer emailed investor questions sent to investorrelations@etonpharma.com. The webcast will be accessible through Eton's investor relations website and will remain available for 30 days after the event.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda farmaceutica focalizzata sui trattamenti per malattie rare, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024. La direzione ospiterà una conference call e un webcast audio alle 16:30 ET per discutere i risultati. L'azienda accetterà domande in diretta durante la chiamata e risponderà alle domande degli investitori inviate via email a investorrelations@etonpharma.com. Il webcast sarà accessibile tramite il sito web per le relazioni con gli investitori di Eton e rimarrà disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (Nasdaq: ETON), una compañía farmacéutica enfocada en tratamientos para enfermedades raras, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024. La gerencia llevará a cabo una llamada de conferencia y una transmisión de audio a las 4:30 p.m. ET para discutir los resultados. La empresa aceptará preguntas en vivo durante la llamada y responderá a las preguntas de los inversores enviadas por correo electrónico a investorrelations@etonpharma.com. La transmisión estará disponible a través del sitio web de relaciones con inversores de Eton y permanecerá accesible durante 30 días después del evento.
Eton Pharmaceuticals (Nasdaq: ETON)는 희귀 질환 치료에 중점을 둔 제약 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 12일 화요일로 예정하였습니다. 경영진은 결과를 논의하기 위해 동부시간 기준 오후 4시 30분에 컨퍼런스 콜 및 오디오 웹캐스트를 개최합니다. 회사는 통화 중 실시간 질문을 받고, investorrelations@etonpharma.com으로 보내진 이메일 투자자 질문에 답변할 것입니다. 웹캐스트는 Eton의 투자자 관계 웹사이트를 통해 접근 가능하며, 행사 후 30일 동안 이용할 수 있습니다.
Eton Pharmaceuticals (Nasdaq: ETON), une entreprise pharmaceutique spécialisée dans les traitements des maladies rares, a prévu d'annoncer ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024. La direction organisera une conférence téléphonique et un webinaire audio à 16h30 ET pour discuter des résultats. L'entreprise prendra des questions en direct pendant l'appel et répondra aux questions des investisseurs envoyées par e-mail à investorrelations@etonpharma.com. Le webinaire sera accessible via le site web des relations avec les investisseurs d'Eton et restera disponible pendant 30 jours après l'événement.
Eton Pharmaceuticals (Nasdaq: ETON), ein auf Behandlungen seltener Krankheiten fokussiertes Pharmaunternehmen, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 auf Dienstag, den 12. November 2024, festgelegt. Das Management wird um 16:30 Uhr ET eine Telefonkonferenz und ein Audio-Webcast abhalten, um die Ergebnisse zu besprechen. Das Unternehmen wird während des Anrufs Live-Fragen entgegennehmen und Antworten auf per E-Mail gesendete Investorenfragen an investorrelations@etonpharma.com geben. Der Webcast wird über die Investor-Relations-Website von Eton zugänglich sein und 30 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Dial in (Audio Only) | Toll-free: 888-596-4144 | |
| Non-toll free: 646-968-2525 | ||
| Access Code: 1144771 | ||
| Webcast: | Click Here | |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q3 2024 earnings?
What time is Eton Pharmaceuticals (ETON) Q3 2024 earnings call?
How can investors participate in Eton Pharmaceuticals (ETON) Q3 2024 earnings call?
